CL
CLPT.US Clearpoint Neuro Inc
- Market cap
- USD 272M
- P/E
- -
- P/B
- 9.97x
- ROE
- -138.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CLPT.US undervalued?
Graham numberThe Graham number of Clearpoint Neuro Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Clearpoint Neuro Inc fundamental analysis
No fundamental analysis for Clearpoint Neuro Inc yet.
Clearpoint Neuro Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Clearpoint Neuro Inc
ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessori…
Full company profileClearpoint Neuro Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Clearpoint Neuro Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 5.75M | 7.38M | 7.35M | 11.2M | 12.8M | 16.3M | 20.6M | 24.0M | 31.4M | 37.0M | 46.8M |
| Gross Profit | 3.11M | 4.48M | 4.92M | 7.28M | 9.12M | 11.1M | 13.5M | 13.6M | 19.1M | 22.7M | 28.7M |
| Operating Income | -7.49M | -6.34M | -5.25M | -4.59M | -6.22M | -13.4M | -16.3M | -22.4M | -19.7M | -24.2M | -33.4M |
| EBITDA | -6.85M | -6.18M | -5.07M | -4.33M | -4.79M | -12.7M | -15.6M | -20.6M | -17.0M | -20.9M | -27.5M |
| Net Income | -8.07M | -7.17M | -6.16M | -5.54M | -6.78M | -14.4M | -16.4M | -22.1M | -18.9M | -25.5M | -37.8M |
| EPS | -2.93 | -0.93 | -0.56 | -0.42 | -0.43 | -0.69 | -0.68 | -0.90 | -0.70 | -0.90 | -1.22 |
| Balance Sheet | |||||||||||
| Total Assets | 7.40M | 13.9M | 7.86M | 11.9M | 29.5M | 65.6M | 55.5M | 42.7M | 39.2M | 97.7M | 113M |
| Total Liabilities | 8.16M | 8.07M | 6.35M | 7.34M | 27.1M | 16.8M | 18.6M | 21.5M | 13.8M | 69.7M | 85.5M |
| Shareholders' Equity | -756K | 5.83M | 1.51M | 4.59M | 2.38M | 48.8M | 36.9M | 21.2M | 25.4M | 28.0M | 27.3M |
| Cash & Short-term Investments | 3.32M | 9.29M | 3.10M | 5.70M | 20.1M | 54.1M | 37.5M | 23.1M | 20.1M | 45.9M | 46.2M |
| Total Debt | 5.61M | 4.92M | 3.48M | 2.46M | 24.1M | 12.3M | 12.0M | 13.9M | 3.57M | 58.2M | 73.7M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -5.82M | -5.99M | -4.63M | -2.85M | -7.81M | -12.7M | -16.2M | -13.7M | -8.95M | -23.9M | -26.8M |
| Capital Expenditure | 101K | 26.8K | 63.5K | 160K | 482K | 168K | 253K | 717K | 275K | 522K | 1.33M |
| Free Cash Flow | -5.92M | -6.02M | -4.69M | -3.01M | -8.29M | -12.9M | -16.4M | -14.4M | -9.23M | -24.4M | -28.1M |
| Ratios | |||||||||||
| ROE | - | -123.0% | -407.9% | -120.8% | -285.3% | -29.5% | -44.6% | -104.3% | -74.5% | -91.1% | -138.6% |
| ROA | -109.0% | -51.6% | -78.4% | -46.4% | -23.0% | -22.0% | -29.6% | -51.8% | -48.3% | -26.1% | -33.5% |
| Net Profit Margin | -140.4% | -97.1% | -83.8% | -49.4% | -52.9% | -88.4% | -80.0% | -92.2% | -60.3% | -69.1% | -80.8% |
| Debt to Equity | - | 0.84x | 2.30x | 0.54x | 10.15x | 0.25x | 0.32x | 0.66x | 0.14x | 2.08x | 2.70x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Clearpoint Neuro Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 204K | 0.01 | - |
| 2021 | USD 432K | 0.02 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:40 on Jul 27, 2016.
Who owns Clearpoint Neuro Inc
- Insiders 5.23%
- Institutions 52.57%
- Public & others 42.20%
- Shares outstanding 32.1M
- Free float 26.1M
Top funds holding CLPT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 854K | 2.66% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 702K | 2.19% | 0.00% | Oct 2026 |
| Rolnik Focus FIL | 500K | 1.56% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 309K | 0.96% | 0.00% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 268K | 0.84% | -0.38% | Oct 2026 |
| Vanguard Russell 2000 ETF | 164K | 0.51% | +1.13% | Sep 2026 |
| Fidelity Extended Market Index | 144K | 0.45% | -3.95% | Sep 2026 |
| Stt Strt®SPDR®S&PKenshoNwEcosComposETF | 123K | 0.38% | +0.08% | Oct 2026 |
| Stt Strt® SPDR® S&P®HlthCrEqpmntETF | 113K | 0.35% | 0.00% | Oct 2026 |
| SEB Nordamerikafond Småbolag | 89.8K | 0.28% | 0.00% | Sep 2026 |
| iShares Micro-Cap ETF | 86.0K | 0.27% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 68.6K | 0.21% | 0.00% | Sep 2026 |
| DWS Global Small Cap S | 59.5K | 0.19% | 0.00% | Aug 2026 |
| Fidelity Total Market Index | 56.9K | 0.18% | -0.05% | Sep 2026 |
| Bridge Builder Small Cap Fund | 54.1K | 0.17% | 0.00% | Oct 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 52.7K | 0.16% | 0.00% | Sep 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 52.1K | 0.16% | -6.48% | Sep 2026 |
| Fidelity Series Total Market Index | 46.4K | 0.14% | 0.00% | Sep 2026 |
| Rolnik Conviction V FI | 44.0K | 0.14% | +29.41% | Oct 2026 |
| Nuveen Small Cap Blend Idx R6 | 37.3K | 0.12% | 0.00% | Aug 2026 |
Top institutions holding CLPT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 2.38M | 7.42% | +14.26% | Jun 2026 |
| Mak Capital One LLC | 2.38M | 7.41% | +24.95% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.23M | 3.85% | -0.87% | Jun 2026 |
| State Street Corp | 817K | 2.55% | +20.11% | Jun 2026 |
| Geode Capital Management, LLC | 750K | 2.34% | +6.26% | Jun 2026 |
| Lane Generational LLC | 445K | 1.39% | -8.63% | Jun 2026 |
| UBS Group AG | 429K | 1.34% | -0.86% | Jun 2026 |
| Millennium Management LLC | 358K | 1.12% | +54.19% | Jun 2026 |
| Brown Advisory Holdings Inc | 326K | 1.02% | 0.00% | Jun 2026 |
| Compass Financial Management LLC | 296K | 0.92% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 240K | 0.75% | +76.31% | Jun 2026 |
| Northern Trust Corp | 231K | 0.72% | +10.29% | Jun 2026 |
| Pier Capital, LLC | 223K | 0.69% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 213K | 0.67% | +3.64% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 195K | 0.61% | -31.68% | Jun 2026 |
| Tudor Investment Corp Et AL | 174K | 0.54% | +10.70% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 166K | 0.52% | +27.65% | Jun 2026 |
| Two Sigma Investments LLC | 155K | 0.48% | -26.53% | Jun 2026 |
| Bank of New York Mellon Corp | 152K | 0.47% | +5.58% | Jun 2026 |
| Parsons Capital Management Inc | 149K | 0.46% | -0.03% | Sep 2026 |
Clearpoint Neuro Inc company profile
- Company name
- Clearpoint Neuro Inc
- Ticker
- CLPT.US
- Exchange
- USA Stocks
- Listed since
- Feb 12, 2020
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 172
- Fiscal year end
- December
- Address
- 120 S. Sierra Avenue, Solana Beach, CA, United States, 92075
- Phone
- 888 287 9109
- Website
- clearpointneuro.com
About Clearpoint Neuro Inc
ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula. It also provides ClearPoint software, which guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring; ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue; and IRRAflow system, an active fluid exchange platform. In addition, the company offers consulting services to its pharmaceutical and other medical technology partners, such as benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and translation from the preclinical to the clinical setting. It has licenses and collaboration agreements with Koninklijke Philips N.V., UCB Biopharma SRL, Clinical Laserthermia Systems AB, University of California, San Francisco, and NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Clearpoint Neuro Inc management
8- Mr. Joseph Michael BurnettPresident, CEO & Director · born 1977
- Mr. Danilo D'AlessandroChief Financial Officer · born 1985
- Mr. Jeremy L. StigallChief Business Officer · born 1984
- Mr. Mazin SabraChief Operating Officer · born 1980
- Mr. Robert C. KornSenior Vice President of Sales & Business Development · born 1965
- Dr. Paul S. Larson FAANS, M.D.Chief Medical Officer
- Ms. Mary McNamara-Cullinane RACSenior Vice President of Regulatory Affairs
- Ms. Megan FaulkenberrySenior Vice President of Quality